chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report received from a healthcare professional on 17 May 2012. A one-month-old female patient, whose medical history and concomitant medications were not reported, received a dose of FLUZONE on 08 May 2012. It was reported that the patient received a dose of FLUZONE (lot number: U8507AA, route and site of vaccination not reported) on 10 April 2012. On 8 May 2012, she received second dose of FLUZONE (lot number, route and site of vaccination not reported). Hence the patient received an extra dose of FLUZONE. The lot number U8507AA was not valid. At the time of this report, the patient did not have any adverse event. List of documents held by sender: none.
back and chest are achy; lump on collarbone next to neck on same side as injection; feels pretty achy/ swollen lymph node hurts; feels tired; swollen lymph node; This spontaneous case was reported by a consumer and describes the occurrence of CHEST PAIN (back and chest are achy), NODULE (lump on collarbone next to neck on same side as injection), PAIN (feels pretty achy/ swollen lymph node hurts), FATIGUE (feels tired) and LYMPHADENOPATHY (swollen lymph node) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 010A21A and 021B21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetic. Concomitant products included NAPROXEN SODIUM (ALEVE) for an unknown indication.   On 27-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Apr-2021, the patient experienced CHEST PAIN (back and chest are achy), NODULE (lump on collarbone next to neck on same side as injection), PAIN (feels pretty achy/ swollen lymph node hurts), FATIGUE (feels tired) and LYMPHADENOPATHY (swollen lymph node). At the time of the report, CHEST PAIN (back and chest are achy), NODULE (lump on collarbone next to neck on same side as injection), PAIN (feels pretty achy/ swollen lymph node hurts), FATIGUE (feels tired) and LYMPHADENOPATHY (swollen lymph node) outcome was unknown.
I came back from vacation on 04/01/2023; the next afternoon, I had a fever and ended up having a fever that wouldn't break even with taking TYLENOL. I tested negative for COVID-19 though. On 04/04/2023, I lost my taste and sense of smell. I tested again twice, and both tests came back positive. I began coughing so my pulmonologist told me to go to the emergency room being that I'm severely asthmatic. He was afraid I could have a pulmonary embolism as well. When I got to the ER, they did a CAT scan and x-ray to check for pneumonia nor a pulmonary embolism. They also gave me LEVAQUIN blood thinner injection and prescribed me PAXLOVID and sent me home. I took my prescription; even after taking my prescription, I haven't regained my sense of taste and smell, and my asthma is still triggered. I have an upcoming appointment with my pulmonologist for additional follow-up. Six weeks prior, I had pneumonia and then following I caught COVID-19 that I'm currently reporting.
have a smell and taste of decaying fruit; have a smell and taste of decaying fruit; This is a spontaneous report from a contactable consumer reported for herself. A 32-years-old female patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Solution for injection), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) (vaccination at the age of 32 years) as single dose for covid-19 immunization. The patient medical history and concomitant medications were not reported. The patient previously took first dose of bnt162b2 on an unknown date for covid-19 immunization. The patient reported that she had both doses of the Pfizer COVID Vaccine. After the second dose, she reported to have a smell and taste of decaying fruit on unknown date. She wants to know if other people have reported that as a side effect and if there is anything she must do. The outcome of the events was unknown.  Information on the lot/batch number has been requested.
Bruise lasting longer than 3 weeks and lingering pain in injection area. Hot to the touch at injection site
Numbness in heel of right hand lasting 1 week  Headache within 1 hour lasting 36 hours post shot. Within 40 minutes, lasting 3 hours  bi-lateral  biceps and triceps aching. Fatigue for 5 days. Irritable for 6 days
Case number PHEH2016US009025, is an initial spontaneous report received from a pharmacist via phone on 11 Apr 2016. This report refers to a 16 years old female patient. Medical history and concomitant medications were not reported. The patient was vaccinated with FLUVIRIN (Batch number: not reported) in Sep 2015. The patient was tested positive for flu strain B since she received vaccination. Outcome of the event was unknown. Seriousness and causality of the event was not reported. Seriousness of the event "Influenza B virus test positive" was upgraded based on the available information in the source document.
The pt was diagnosed with ITP in July, 96. Began showing signs of ill health within 2 1/2 weeks of vaccination. The pt developed a rash and gradually began developing more and more bruises. Platelets were extremely low. Constant fluctuating. As low as 5,000. This lasted for about 6 months or so. Weekly blood tests and doctor visits. The pt was finally released from his MD about 2 years later (1998). Received prednisone for a month. Other than that no other treatment just a wait and monitor decision was made. FU received 8/14/00 gives diagnosis of ITP on 7/2/96.
Fever to 106, marked tremulousness, incoordination mod amt (staggered a little, couldn't drink from a cup, somnolence
Red triangular raised bump patch (non-itch) of skin from right ear to the middle of the throat. Appeared by late afternoon of the day the vaccine was administered. The rash lasted 4 to 5 days, turn brown and skin sloughed off, skin over the area of the throat still feels different now.  Also I have been experiencing a change in smell sense. I smell a wood/ash smell numerous time through out the day since receiving the vaccination, I can kind of take it when I smell the ash/wood smell.
Hot, tingling feeling in arm just below injection site.....drippy sensation going down about 4 inches below site.....within 2-3 minutes....lasted 15 minutes 25 minutes after injection itchy spot on opposite hand......small hive with redness......lasted 10 minutes 75 minutes later itchy lower neck and upper chest with a red blotchy rash. About a 4x5 inch area, also itchy mildly  scalp.........lasted about 20 minutes
Soreness and tenderness at the injection site; General but mild full body aches; This is a spontaneous report from a contactable consumer (patient). A 49-year-old non pregnant female patient received bnt162b2 (FIZER-BIONTECH COVID-19 mRNA VACCINE, solution for injection, Lot Number: EL3247), dose 1 via an unspecified route of administration, administered in left arm on 23Feb2021 09:45 (at age of 49-year-old) as dose 1, single for covid-19 immunization at clinic. Medical history included breast cancer survivor. Concomitant medications (received within 2 weeks of vaccination) included cyanocobalamin (B12 [CYANOCOBALAMIN], 1000 mg), colecalciferol (D3, 2000 IU). No allergies to medications, food, or other products. The patient was not pregnant at the time of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID. Since the vaccination, the patient was not tested for COVID-19. On 23Feb2021 16:00, the patient experienced soreness and tenderness at the injection site, general but mild full body aches. The outcome of events was recovering.  Follow-up attempts completed. No further information expected.
neuropathy; muscle pain; muscle weakness; brain fog; insomnia; twitching; tinnitus; blurry vision; This is a spontaneous report received from contactable reporter(s) (Pharmacist) from medical information team.  A female patient in her 50's received bnt162b2 (BNT162B2), administration date 31Aug2021 (Lot number: XC3182, Expiration Date: Aug2021) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (1st dose, lot: EW0167), administration date: Aug2021, for COVID-19 Immunization. The following information was reported: NEUROPATHY PERIPHERAL (medically significant) with onset 2021, outcome "unknown", described as "neuropathy"; MYALGIA (medically significant) with onset 2021, outcome "not recovered", described as "muscle pain"; MUSCULAR WEAKNESS (medically significant) with onset 2021, outcome "not recovered", described as "muscle weakness"; FEELING ABNORMAL (non-serious) with onset 2021, outcome "unknown", described as "brain fog"; INSOMNIA (non-serious) with onset 2021, outcome "unknown", described as "insomnia"; MUSCLE TWITCHING (non-serious) with onset 2021, outcome "unknown", described as "twitching"; TINNITUS (non-serious) with onset 2021, outcome "unknown", described as "tinnitus"; VISION BLURRED (non-serious) with onset 2021, outcome "unknown", described as "blurry vision".  Clinical Course included: Caller states the patient was concerned that the lot number of the 2nd dose of her Pfizer Covid vaccine was maybe expired and caller does not think it is expired because she found a report on the beyond use date. Caller states the patient got her Pfizer Covid vaccine at another pharmacy. Caller states the patient had the 1st dose of the Pfizer Covid vaccine with lot EW0167 and does not know the date of that but it was 3 weeks from her 2nd dose which was administered caller clarifies on 31Aug2021 with lot XC3182; states she has no expiry date but the patient thinks the expiry date for the 2nd dose of her vaccine is Aug2021 and it would be the last day of that month and she has no NDC numbers to provide.  Caller states for causality, she does not think the Pfizer Covid vaccine is related to the reported events and she would not say the reported events are life threatening but they are medically significant since the patient has had the reported events since Sep; states the reported events began when the patient had the 2nd dose of the Pfizer Covid Vaccine.; Sender's Comments: Based on the information in the case report, a possible causal association between the events and suspect drug BNT162B2 cannot be excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
Information has been received from a medical assistant concerning an 18 year old female who in approximately 1991, "when she was 1 year of age" was vaccinated with MMR II. On 31-OCT-2008 the patient was vaccinated with MMR II. The medical assistant states the patient still has low titer for measles. The patient's titers are not low for mumps or rubella. No further information is available.
Patient has received pfizer vaccine on 3/17/21, 4/14/21, and 11/24/21. COVID positive on 2/15/22. Presented to ER on 2/15/22. He was resuscitated with IV fluids moderately aggressively in the emergency  room with 2 L of normal saline there.  Then we backed down on the IV fluid  rates to 150 cc an hour given his underlying ischemic cardiomyopathy and the  concern to avoid decompensated heart failure.  He remained on IV fluids for  the next 4 days.  His BUN and creatinine progressively improved, dropping from  181 and 4.1 on admission to 68 and 2.0 on the day of discharge, which is  basically back to baseline.  His breathing remained comfortable throughout his  stay.  He remained afebrile and he was empirically treated with Rocephin.   His urine looked extremely abnormal, but urine cultures revealed multiple  organisms, so the significance of this was unclear, although he has had  frequent recurrent UTIs well documented in Epic.  Blood cultures all remained  negative.    He clinically did well with regard to his respiratory status.  He remains well  saturated on room air on the day of discharge with sats in the 99% range.   His Accu-Cheks remained acceptable as well, although his oral intake still  remained marginal. Discharged on 2/20/22
Service member (SM) was in his usual state of excellent health prior to May 2010. SM received Typhoid and Meningococcal vaccine on 9 Feb 2010, and had received an inactivated H1N1 flu vaccine in Jan 2010. He denies any unusual or prolonged reactions within the first week following vaccine receipt. He does not recall any viral-type symptoms just prior to or on the days of vaccine receipt. He completed a physical exam in Feb 2010 and reported feeling well. However, his fasting serum glucose level on 9 Feb 2010 was 211. Sometime in mid-April 2010, SM noted increased thirst and urination and weakness. Between Feb 2010 and time of diagnosis in May 2010, SM lost 25 pounds (BMI 21.62). Also, by the time of diagnosis, SM complained of abdominal pain and constipation, but denied nausea and/or vomiting. When he sought evaluation on 3 May 2010, his serum glucose level was 258, his HgbA1c was 11.8 and his urine was positive for glucose and ketones. He He was hospitalized for 5 days for hydration, electrolyte replacement, and insulin titration, as well as diabetes self management training. He was discharged on once daily Lantus with additional supplementation for hyperglycemia using Novolog. Since that time, SM has been followed through local military health care providers, as well as by civilian Endocrinologist. SM denies a history of elevated glucose or blood pressure levels or history of hypertension prior to T1DM diagnosis. he does not recall a history of recent infection or symptoms of cough, fever, sinus symptoms, congestion or diarrhea prior to his diagnosis. He was active with sports and PT and had a normal BMI (23.92) prior to diagnosis. SM has no family history of diabetes. DX: Type 1 Diabetes Mellitus.
This spontaneous report as received from a 63 year old female patient. The patient did not have drug reactions/allergies. The patient had mild shingles prior to receiving the vaccine. On 11-DEC-2012 the patient was vaccinated with ZOSTAVAX (dose, route and lot # were unknown). The patient received a flu shot (manufacturer unknown) on the same day. The patient had Various other medications including TOPROL and SYNTHROID. The patient reported that after receiving the ZOSTAVAX vaccine she developed a red rash 1-2 days later and the rash had little red dots, and sometimes appeared in hives in the same location that her prior shingles outbreak had occurred. The outcome of event was unknown. Treatment was given: SINGULAIR, ZYRTEC, ZANTAC and Cortisone cream. Other lab work was taken for other conditions. The patient had sought unspecified medical attention. Additional information has been requested.
10min p/vax hives noted on vaccinated arm;DPH given & resolved w/in 30min;
Shot give at 11:30 Am at 7:30 PM arm swollen and red tightening in throat and got funny  Went to ED and received benadryl and epi
I received the first moderna vaccine in January then got Covid; I never received the second shot can I still get it; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (I received the first moderna vaccine in January then got Covid) and PRODUCT DOSE OMISSION ISSUE (I never received the second shot can I still get it) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (I received the first moderna vaccine in January then got Covid) and PRODUCT DOSE OMISSION ISSUE (I never received the second shot can I still get it). At the time of the report, COVID-19 (I received the first moderna vaccine in January then got Covid) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (I never received the second shot can I still get it) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medications details were not reported by the reporter. Treatment details was not reported by the reporter.
Pneumonia of both lungs, non-hypoxic.  Encephalopathy with greater than usual confusion.
Pt vaccinated with DTP/OPV on 16OCT90 child admitted to hosp w/temp of 104, vomitting & lethargy.
pt stated metal taste, burping, fatigue, vomiting, dizziness . First night dizziness, then most symptoms next day or the following day
Left arm with 12 cm X 12 cm indurated firm red swollen area. Warm tender to touch no discharge. Ice applied. Vaccine given 5/30/07 with reddness swelling pain itching starting 24  hours later. RX Keflex 250/5 1 tsp BIDX10d
One to two days following vaccination, the patient developed a rash on his face as well as reported fevers.
The patient developed a painful, swollen, mildly red area on her left posterior upper arm.  The patient also experienced an increased heart rate (up to 150 bpm), fevers (up to 40.8 C), and increased white blood cell count (up to 26,000).  She was started on naproxen 250mg by mouth three times daily. Discharge summary states hypotensive, ataxic. msv
This spontaneous report was received from a pharmacist referring to her mother, a currently 71 year old female patient. The patient's pertinent medical history, concurrent conditions or concomitant medications were not reported. On an unknown date (reported as "years ago"), the patient was vaccinated with PNEUMOVAX23 (lot#, dose, frequency and route of administration were unspecified) for routine vaccination (prophylaxis). On an unknown date, after receiving PNEUMOVAX23, the patient developed a big bump on her arm at a department of health. It was stated that the big bump (injection site mass) lasted a week. It was also reported that it was not necessary intervention to prevent serious criteria, that the adverse event was not significant disability or incapacity or life threatening, and that the patient was not hospitalized. The relatedness assessment between PNEUMOVAX23 and injection site mass was not provided. This is one of several reports from the same source. Additional information has been requested.; Sender's Comments:  US-009507513-1705USA014939: US-009507513-1705USA014940:
This medically confirmed spontaneous initial (initial receipt 13-Jan-2015) concerns a 77-year-old female patient with no relevant patient history. On 23-Dec-2014, the patient received intramuscular AFLURIA (batch number 09449221A) 0.5 mL once for the protection against seasonal influenza virus. Around the 26-Dec-2014, a few days after receiving the injection, the patient began to experience soreness in her arm where the vaccine was administered and her arm was sore after vaccination. The outcome was reported as not yet recovered.
The night of my vax , i started to feel hot and sweaty.  I checked for fever. Was only 98.9.  Roughly 30min later, i started feeling cold sweats.  These went into feeling hot again. Nxt day, o had cold sweaty off and on and was cold.  These cold sweats have continued.  Unfort my blood glucose monitor needed new batteries so, until today, i could only go by how i normally feel if my BS is high or low.  Cold sweats are high.  Today i checked and it was 163.  I have not changed ANY of my diet.  I also have not had issues with my BS going up and down like this before.
pain at the site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (pain at the site) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 026L20A and 012M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 05-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 05-Jan-2021, the patient experienced VACCINATION SITE PAIN (pain at the site). The patient was treated with PARACETAMOL (TYLENOL) for Headache and Fever, at an unspecified dose and frequency. At the time of the report, VACCINATION SITE PAIN (pain at the site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was not included.
Fainted immediately after administration. Came too shortly after by utilizing cold pack and drank cold water. Patient left feeling well after 30 minutes.
Swollen, protruding, and sore lymph node on the left clavicle. This is the same side as the injection site (left upper arm). Dull pain / soreness. The lymph node moves back and forth over my clavicle as I move my neck. Started about 3 hours ago, and is ongoing.
The pt experienced a fever, rash vomiting. Diagnosed with a viral (hand, foot and mouth), coxsackie B virus.
56-year-old male with a past medical history including coronary artery disease, history of prior stroke, COPD, PVD, hyperlipidemia, diabetes, GERD, hypertension is admitted to the hospital 7 days post Pfizer booster shot for acute stroke.  MRI brain revealed numerous, small acute to subacute infarcts along cortex and watershed zones of posterior and middle cerebral arteries and at middle anterior cerebral arteries of right hemisphere with tiny additional infarcts left cerebral hemisphere.  The patient's stroke symptoms resolved rather quickly and he returned to his functional baseline within 24 hours of arrival.
No adverse event reported.  Pt received RabAvert vaccine in gluteal muscle instead of deltoid muscle.
This report was received from manufacturer research and was assigned manufacturer control number HQWYE582221FEB03 concerning a four year old female who on 7/7/98 was vaccinated with a dose of MMR II. In December 2002, the pt developed autism, fever, somnolence and feeding problem. The pt's outcome was unknown. This was originally reported by a physician. Follow-up info received from the physician indicated that on 7/7/98 the pt was vaccinated with a dose of MMR II and a dose of Hibtiter. The pt was last seen in the physician's office on 3/9/00 and had subsequently left the practice and transferred to another physician. The physician noted that the pt must have been diagnosed with autism after leaving her practice. According to the physician, the pt had no significant past medical history and she was only seen in her office for well visits and occasional ear infections/colds. Autism, fever, somnolence and feeding problems were considered to be other important medical events (OMIC). Additional info is not expected.
3-30-21 tingling in right side of lips, could see nothing wrong in mirror, progressed up right cheek, right eye began swelling  then swelled shut, Nurse at  Medical center at this point.  BP was 200/100 at Nurse office.  Initial feeling from Nurse was stroke.  Started Nurse on lisinopril 10 mg daily that day and prednisone 20mg qd for 1 week beginning next day.  With her recent Covid vaccine Nurse then thought Bells Palsey.  As of today, her left eye is tearing, cannot smile, cannot raise eyebrows, difficulty chewing.  No labs were performed per patient.